Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, becau...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of clinical investigation Ročník 131; číslo 5; s. 1 - 11
Hlavní autoři:	Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States American Society for Clinical Investigation 01.03.2021
Témata:	Antigens Apoptosis Biomarkers Biomedical research Cancer Cell injury Complications and side effects Cytokines Cytotoxicity Development and progression Drug therapy Enzyme inhibitors FDA approval Heart diseases Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immune system Inflammation Ligands Lymphocytes Lymphocytes T Myocarditis Myocarditis - chemically induced Myocarditis - diagnosis Myocarditis - immunology Myocarditis - pathology Peptides Proteins Review T cell receptors Thymus gland Toxicity United States
ISSN:	0021-9738, 1558-8238, 1558-8238
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!